Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Progress of Drug Clinical Trial By a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the above mentioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
12 November 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Progress of Drug Clinical Trial By a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Fosun Kairos (Shanghai) Biological Technology Co., Ltd.* (復星凱瑞(上海)生物科技有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*（上海復星醫藥（集團）股份有限公司） (the "**Company**"), initiated the Phase II clinical trial of FKC516 Injection ("**FKC516**") for the treatment of refractory/relapsed B-cell non-Hodgkin lymphoma (r/r B-NHL) in Chinese mainland[1].

II. Basic Information and Research Progress of FKC516

FKC516 is a CD20-targeted autologous CAR-T cell therapy product licensed by the Group (i.e., the Company and its subsidiaries/units, the same applies below). Pursuant to the agreement, the Group enjoys (including, without limitation) the exclusive rights to develop and commercialize the product on a global basis in all disease fields.

As of September 2026, the Group had invested approximately RMB13.37 million (including license fees; unaudited) in total in the research and development of FKC516 at this stage.

As of the date of this announcement (i.e., 12 November 2026), no CAR-T product with the same target has been approved for launch in Chinese mainland.

[1] Excluding Hong Kong, Macau and Taiwan regions for the purpose of this announcement only, the same applies below.

III. Risk Reminder

As required by the relevant regulations, FKC516 is still required to undergo relevant clinical trials in Chinese mainland and obtain approval from the national drug review authority before it can be launched.

The process from drug development and clinical research to launch involves a long period and multiple stages, with various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

12 November 2026

* For identification purpose only